解锁类器官在癌症治疗与转化研究中的潜力:细胞学技术的应用
患者来源类器官模型有望推动癌症诊断及个体化精准医疗,细胞学在其中发挥关键作用。这类三维多细胞结构具有异质性,可维持亲代肿瘤的基因组、转录组和表观基因组模式。本文探讨肿瘤类器官技术,强调细胞学验证是启动类器官培养前的必要步骤,并讨论细针穿刺在类器官构建中的重要性。
要点
- 类器官培养前需用细胞学验证肿瘤组织,确保仅肿瘤组织用于建库。
- 细胞学是简单且成本效益高的类器官开发辅助方法。
- 细针穿刺可用于生成肿瘤类器官,值得重视。
核心结论
- 患者来源类器官模型有助于推进癌症诊断、个体化与精准医学研究。
- 细胞学验证是确保仅肿瘤组织用于类器官开发的必要步骤。
研究设计与样本
- 本文为综述,探讨肿瘤类器官技术及细胞学在类器官开发中的基础应用。
主要发现
- 类器官为三维多细胞结构,具有异质性,可维持亲代肿瘤的基因组、转录组和表观基因组模式。
临床怎么用
- 启动类器官生成前应进行细胞学验证,确保使用肿瘤组织。
- 可采用细针穿刺生成肿瘤类器官。
- 细胞学可作为简单且成本效益高的类器官开发辅助方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patient-derived organoid models hold promise for advancing clinical cancer research, including diagnosis and personalized and precision medicine approaches, and cytology, in particular, plays a pivotal role in this process. These three-dimensional multicellular structures are heterogeneous, potentially maintain the cancer phenotype, and conserve the genomic, transcriptomic, and epigenomic patterns of the parental tumors. To ensure that only tumor tissue is used for organoid development, cytologic validation is necessary before initiating the process of organoid generation. Here, we explore the technology of tumor organoids and discuss the fundamental application of cytology as a simple and cost-effective approach toward organoid development. We also underscore the potential application of organoid development in drug efficacy studies for lung cancer and head and neck tumors. Additionally, we stress the importance of using fine-needle aspiration to generate tumoroids.
引用
- Abd El-Salam MA, Troulis MJ, Pan CX, et al. Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques. Cancer Cytopathol. 2023. PMID: 37843532. doi:10.1002/cncy.22769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。